The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | Exciting new treatments in myeloma
Xavier Leleu, MD, PhD, from the Poitiers University Hospital, Poitiers, France, discusses exciting new treatments in myeloma at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Recent use of immunomodulatory drugs (IMiDs) has shown improved levels of progression free survival. Dr Leleu compares their efficacy to that of proteasome inhibitors. The results of the POLLUX (NCT02076009) trial were ground-breaking, with approximately 70% of patients had not relapsed at 18 months. There is also the potential for lenalidomide and dexamethasone to replace VMP and KMP, as it is less cytopenic.
